Table 2. Treatment details of each individual patient.
| No | Age at onset (years) | Gender | GN | SCr at diagnosis (mg/dL) | Urinary protein at diagnosis (g/day) | Previous IS | Response before RTX | Number of relapses prior to rituximab | Follow-up after RTX therapy (years) | SCr follow-up (mg/dL) | Urinary protein follow-up (g/day) | Status at last follow-up | Complications of RTX therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 24 | M | MN | 0.7 | 8.0 | Pd, CyA, TAC, Cp | CR | 2 | 31 | 0.9 | 1.1 | PR | No |
| 2 | 35 | F | MN | 0.8 | 3.5 | Pd, CyA | CR | 1 | 4 | 0.6 | 0.9 | PR | No |
| 3 | 76 | M | MN | 1.3 | 7.6 | CyA, MMF | PR | 1 | 13 | 1.9 | 5.4 | NR | No |
| 4 | 76 | M | MN | 1.3 | 9.3 | Pd, CyA | CR | 1 | 6 | 1.9 | 7.5 | NR | No |
| 5 | 28 | F | MN | 0.7 | 2.6 | CyA | PR | 0 | 8 | 0.8 | 2.4 | NR | No |
| 6 | 42 | M | MN | 1.5 | 6.6 | Pd, Cp | CR | 1 | 16 | 1.1 | 0.3 | CR | No |
| 7 | 70 | M | MN | 1.4 | 8.0 | RTX | * | 0 | 5 | 1.3 | 0.2 | CR | infusion reactions |
| 8 | 37 | F | FSGS | 1.7 | 0.7 | Cp | NR | 0 | 5 | 2.3 | 0.1 | RD | No |
| 9 | 7 | M | FSGS | 0.2 | 3.7 | Pd, TAC | PR | 0 | 13 | 0.8 | 7.0 | NR | No |
| 10 | 23 | M | FSGS | 0.8 | 11.8 | Pd, MMF | CR | 1 | 8 | 0.8 | 0.5 | CR | No |
| 11 | 15 | M | FSGS | 0.4 | 3.9 | Pd | SD | 0 | 4 | 0.6 | 0.1 | CR | No |
| 12 | 53 | F | LN | 0.9 | 1.2 | Pd | SD | 0 | 1 | 1.1 | 1.3 | NR | No |
| 13 | 26 | F | LN | 0.8 | 3.8 | Pd, Cp, MMF | PR | 0 | 13 | 0.8 | 0.0 | CR | respiratory infection |
| 14 | 47 | F | LN | 0.5 | 1.0 | Pd, MTX, MMF | PR | 1 | 7 | 0.6 | 0.0 | CR | No |
| 15 | 32 | M | LN | 2.4 | 16.9 | Pd, Cp, MMF | PR | 1 | 7 | 6.7 | 10.0 | RD | No |
| 16 | 66 | M | V | 8.0 | 0.0 | Pd, Cp, RXT | * | 0 | 2 | 3.3 | 0.1 | PR | No |
| 17 | 66 | M | V | 1.5 | 3.1 | Pd, RTX | * | 0 | 3 | 1.6 | 0.2 | CR | infusion reactions |
| 18 | 46 | F | V | 2.5 | 0.4 | Pd, Cp, RXT | * | 0 | 1 | 1.2 | 0.0 | CR | No |
| 19 | 63 | F | V | 1.9 | 0.1 | Pd, RTX | * | 0 | 0 | 1.4 | 0.1 | CR | No |
Cp: cyclophosphamide; CyA: cyclosporine A; CR: complete remission; F: Female; FSGS: focal segmental glomerulosclerosis; MN: membranous nephropathy; LN: lupus nephritis; M: male; MTX: metotrexato; MMF: mycophenolate mofetil; NR: no-response; Pd: prednisolone; PR: partial remission; RPRF: rapidly progressive renal failure; RD: renal deterioration; RTX: rituximab; SD: Steroid-dependency; V: vasculitis;
*
RTX as first therapy.